Volume 13, Issue 1 (vol-1 2007)                   Intern Med Today 2007, 13(1): 5-9 | Back to browse issues page

XML Persian Abstract Print

1- , hr_joshaghani@yahoo.com
Abstract:   (10176 Views)
Background and Aim: Despite of success in treatment of cardiovascular disease by drugs and other methods, cardiovascular disease and myocardial infarction are the most common causes of death in developing countries. Many reports spread about correlation between free radicals and increase of homocysteine with atherosclerosis pathogenesis. The aim of this research was study of correlation between elevations of homocysteine with changes of superoxide dismutase (SOD) activity after myocardial infarction. Materials and Methods: This research was a descriptive cross-sectional study that performed in 2006. In fasting condition, blood was taken from 48 patients and 48 health people under 76 years. Serum homocysteine determined by ELISA method, erythrocyte SOD (rSOD) activity assayed by Randox company kit and serum SOD (sSOD) activity assayed by Cayman chemical company kit. Results: In patients group was 36 men and 12 women in controls group was 29 men and 19 women. The mean of homocysteine in patients were 30.3±5.3 µmol/L and in controls were 11.1±3.1 µmol/L, that was significant differences between two groups (P<0.001). The mean activity of sSOD in patients and controls were 2705±2078 U/g Hb and 2509±2450 U/g Hb, respectively. The mean activity of rSOD in patients and controls were 47.8±25.6 U/mL, 44.8±24.6 U/mL, respectively. Conclusion: In this study was observed increase in homocysteine, sSOD and rSOD in patients compare to controls however increase of SOD was not significant. To seem, elevation of SOD is due to cellular damages. This enzyme inhibits free radicals.
Full-Text [DOC 127 kb]   (7809 Downloads)    
Type of Study: Original | Subject: Internal Medicine
Received: 2008/02/23 | Published: 2007/04/15

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.